

Jahresabschluss 2021

Felix Burkhard, CFO


Generalversammlung, 11. Mai 2022

Galenica – Gesundheit und Wohlbefinden liegen uns am Herzen.



Ausserordentliches Wachstum 2021

Nettoumsatz (in Mio. CHF)



**COVID-19
Initiativen
+3.1%**



**Starkes Wachstum
im Bereich «seltene
Krankheiten»**

MEDI SERVICE
Apothekes Farmacia Pharmacie



M&A




**Marktanteilsgewinne
im Grosshandels-
geschäft mit Ärzten**



Guidance für Nettoumsatz 2022


in Mio. CHF



**Nettoumsatz der Galenica Gruppe
2022 mindestens auf Vorjahresniveau**

Rekordergebnis 2021

EBIT adjustiert²⁾ (in Mio. CHF)



**COVID-19
Initiativen¹⁾
CHF 25 Mio.**




**Verkauf Gebäude
Hauptsitz
CHF 9.4 Mio.**



- 1 Der Einfluss der COVID-19 Initiativen umfasst den Nettoumsatz mit PCR-, Antigen-Schnell- und Selbsttest sowie Impfungen, EBIT Einfluss geschätzt
- 2 Ohne Einfluss von IAS 19 and IFRS 16, siehe Geschäftsbericht 2021, Kapitel «Alternative performance measures»

Guidance für EBIT 2022

in Mio. CHF



2021

2022


- COVID-19 Initiativen
- Verkauf Liegenschaft Hauptsitz
- Normales Business

**EBIT adjustiert¹⁾ +5% bis +10%,
ohne ausserordentliche Ergebnisse
aus den COVID-19 Initiativen
(CHF 25 Mio.) und dem
Immobilienverkauf (CHF 9.4 Mio.)**

¹ Ohne Einfluss von IAS 19 and IFRS 16, siehe Geschäftsbericht 2021, Kapitel «Alternative performance measures»

Investitionen in die Zukunft

in Mio. CHF



Investitionen in immaterielle Anlagen:

- SAP Implementierung bei Alloga/Galexis
- Digitale Infrastruktur bei Galenica für Omni-channel Programm

Investitionen in Sachanlagen:

- Renovation des Logistikzentrums in Ecublens
- Renovation von Apotheken

in % vom Nettoumsatz


1.6%

1.6%

Starke Bilanz

in Mio. CHF

- Eigenkapital adjustiert¹⁾
- Nettoverschuldung adjustiert¹⁾



Debt coverage adjustiert²⁾


1.7x

1.0x

¹ Einzelheiten zu den Bereinigungen im Geschäftsbericht 2021, Kapitel «Alternative performance measures»

² Nettoverschuldung adjustiert / EBITDA adjustiert (ohne Einflüsse von IAS 19 und IFRS 16), siehe Geschäftsbericht 2021, Kapitel «Alternative performance measures»

Starke und nachhaltige Dividendenerhöhung



**Guidance für Dividende 2022:
mindestens gleiche Höhe wie 2021**

¹ Gemäss Vorschlag an die Generalversammlung vom 11. Mai 2022

² Dividende pro Aktie im Verhältnis zum Aktienkurs am Bilanzstichtag

Mit Vollgas auf Kurs bleiben



Disclaimer

Disclaimer Galenica

Certain statements, beliefs and opinions in this presentation are forward-looking, which reflect the Company's or, as appropriate, the Company's directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this presentation as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its of their parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this presentation or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation.

Disclaimer IQVIA

The analyses, their interpretation, and related information contained herein are made and provided subject to the assumptions, methodologies, caveats, and variables described in this report and are based on third party sources and data reasonably believed to be reliable. No warranty is made as to the completeness or accuracy of such third-party sources or data. In all cases where historical results are presented or past performance is described, we note that past performance is not a reliable indicator of future results and performance.

Copyright ©2022 IQVIA. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States and various other countries.